Rapid Readouts

Dr. Kathryn C. Arbour presents preliminary findings from a Phase 1 study showing that zoldonrasib, a selective RAS(ON) G12D inhibitor, demonstrates encouraging antitumor activity and a manageable safety profile in patients with previously treated KRAS G12D–mutant non–small cell lung cancer.

Asciminib Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase in the Pivotal Phase 3 ASC4FIRST Study: Week 96 Update

Dr. Jorge E. Cortes presents updated week 96 results from the Phase 3 ASC4FIRST study, showing that asciminib continues to demonstrate superior efficacy and a more favorable safety profile compared with investigator-selected TKIs in newly diagnosed chronic-phase CML, reinforcing its potential as a standard of care.

ENGOT-EN5/GOG-3055/SIENDO study

Dr. Debra Richardson presents a subgroup analysis of the SIENDO trial, showing that selinexor maintenance therapy significantly improves progression-free survival and delays subsequent treatment in patients with TP53 wild-type advanced or recurrent endometrial cancer, with manageable safety and potential long-term benefit.

Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFRm NSCLC: Updated overall survival analysis from the LAURA study

Suresh S. Ramalingam, MD, FACP, FASCO, presents updated overall survival data from the Phase 3 LAURA study, demonstrating that osimertinib after chemoradiotherapy provides clinically meaningful progression-free survival benefits and favorable survival trends in patients with unresectable stage III EGFR-mutated NSCLC.

Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702

Dr. Benjamin Weinberg presents findings from a ctDNA-based analysis of the CALGB/SWOG 80702 trial, showing that circulating tumor DNA status may help identify patients with stage III colon cancer who could benefit from celecoxib added to standard adjuvant chemotherapy, offering a potential biomarker-driven approach to personalized treatment.

AGAVE-201

Dr. Catherine Lee presents a post-hoc analysis of the AGAVE-201 trial, demonstrating that axatilimab achieves consistent overall response rates in patients with chronic graft-versus-host disease regardless of prior lines of therapy, with rapid and durable responses, particularly following ruxolitinib, and a favorable safety profile.

Dr. Fred Saad presents a post-hoc analysis of the Phase 3 ARANOTE trial, demonstrating that darolutamide plus androgen-deprivation therapy significantly improves radiographic progression-free survival and delays metastatic castration-resistant prostate cancer in patients with metastatic hormone-sensitive prostate cancer, with consistent efficacy across disease volume subgroups and a favorable safety profile.

Tagraxofusp Achieves Anti-tumor Activity With Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial

Marina Konopleva, MD, presents a subanalysis of a pivotal trial evaluating tagraxofusp in treatment-naïve BPDCN, demonstrating its potent anti-tumor activity, rapid clearance of peripheral blasts, and restoration of normal hematopoiesis without cumulative myelosuppression.

Dr. Heinz-Josef Lenz presents first results from the CheckMate 8HW trial, demonstrating that nivolumab plus ipilimumab significantly improves progression-free survival and overall response rates compared to nivolumab monotherapy in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer across all lines of therapy.

CDAC CLL

Dr. Constantine S. Tam presents preliminary results from the Phase 1 CaDAnCe-101 study, highlighting the promising efficacy and safety of the BTK degrader BGB-16673 in heavily pretreated patients with relapsed or refractory CLL/SLL, including those with BTK inhibitor resistance and Richter transformation.

Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma

Dr. Wojciech Jurczak presents first disclosure results from the EPCORE DLBCL-3 trial, demonstrating that fixed-duration subcutaneous epcoritamab monotherapy achieves high response rates with a manageable safety profile in older, anthracycline-ineligible patients with previously untreated large B-cell lymphoma.

Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

Dr. Elias K. Mai presents final progression-free survival results from the Phase 3 GMMG-HD7 trial, demonstrating that adding isatuximab to lenalidomide, bortezomib, and dexamethasone (Isa-RVd) significantly improves minimal residual disease negativity and reduces the risk of progression or death in transplant-eligible patients with newly diagnosed multiple myeloma.

Phase 3 AMPLIFY Trial

Dr. Alan Skarbnik discusses interim findings from the Phase 3 AMPLIFY trial, highlighting the efficacy and safety of fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, compared to chemoimmunotherapy for treatment-naive chronic lymphocytic leukemia.

RLY-2608

Sarah Sammons, MD, highlights ReDiscover trial findings, showcasing the durable efficacy, potent mutant-selective targeting, and favorable safety profile of RLY-2608 combined with fulvestrant in patients with PIK3CA-mutant HR+/HER2− advanced breast cancer, validating its potential as the first allosteric, pan-mutant PI3Kα inhibitor.

BOVen

Dr. Jacob Soumerai provides a comprehensive 5-year follow-up on the multicenter Phase II trial of the BOVen regimen (zanubrutinib, obinutuzumab, and venetoclax) in treatment-naïve chronic lymphocytic leukemia, highlighting sustained undetectable minimal residual disease rates, retreatment outcomes, and the prognostic significance of MRD kinetics (ΔMRD400).

RMC-6236

Dr. Brian Wolpin discusses updated safety and efficacy results from the Phase 1 study of RMC-6236, a RAS(ON) multi-selective inhibitor, highlighting its promising activity, manageable safety profile, and encouraging survival outcomes in patients with RAS mutant pancreatic ductal adenocarcinoma.

Dr. Jorge E. Cortes provides a comprehensive overview of the 5-year follow-up results from the Phase 2 OPTIC study, showcasing the long-term efficacy, safety, and mutational analysis of ponatinib in patients with chronic-phase chronic myeloid leukemia, including outcomes related to dose modifications and mutation evolution.

LTE-1 ASPEN LTFU

Dr. Shirley D’Sa highlights the 5.8-year follow-up results from the ASPEN long-term extension study, demonstrating the durable efficacy, deepening responses, and favorable safety profile of zanubrutinib in patients with Waldenström macroglobulinemia, including those with high-risk genetic mutations.

Data from an Ongoing Phase 1/1b Study BGB-11417-101

Dr. Jacob D. Soumerai presents updated data from the BGB-11417-101 study, highlighting the high efficacy, tolerability, and sustained minimal residual disease clearance achieved with the novel combination of sonrotoclax and zanubrutinib in patients with treatment-naïve chronic lymphocytic leukemia.

Preliminary Results from the IMMagine-1 Trial

Ciera Freeman, MD, PhD, presents the results of the phase 2 iMMagine-1 trial, highlighting preliminary results of anitocabtagene autoleucel (anito-cel), an innovative BCMA-directed CAR T-cell therapy demonstrating deep and durable responses in relapsed/refractory multiple myeloma with a manageable safety profile.

Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Dr. Vania Hungria presents the Phase 3 DREAMM-7 trial results, demonstrating that belantamab mafodotin, bortezomib, and dexamethasone (BVd) achieved a statistically significant and clinically meaningful overall survival benefit over daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma, with deep, durable responses and manageable safety outcomes.

Glofit-GemOX

Dr. Haifaa Abdulhaq presents results from the global Phase III STARGLO trial, demonstrating the superior overall survival, progression-free survival, and complete response rates of glofitamab combined with gemcitabine and oxaliplatin (Glofit-GemOx) versus rituximab-based therapy (R-GemOx) in relapsed/refractory diffuse large B-cell lymphoma, with a tolerable safety profile.

Dr. Constantine S. Tam presents an OncLive Rapid Readout on the zanubrutinib extension study, highlighting deep and durable responses with zanubrutinib, alone or in combination with obinutuzumab, in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients, with impressive 72-month progression-free survival rates and a favorable long-term safety profile.

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Waldenström Macroglobulinemia: Results From the Phase 1 CaDAnCe-101 Study

Dr. John F. Seymour presents preliminary results from the Phase 1 CaDAnCe-101 study, highlighting the efficacy and safety of the BTK degrader BGB-16673 in relapsed or refractory Waldenström macroglobulinemia, demonstrating high response rates, rapid improvements in cytopenias, and promising activity across diverse mutation profiles.

Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia

Dr. Amer Zeidan presents interim Phase 1a results from the KOMET-007 trial, demonstrating the safety and robust clinical activity of ziftomenib combined with intensive chemotherapy (7+3) in newly diagnosed adverse-risk NPM1-mutated and KMT2A-rearranged acute myeloid leukemia, highlighting high response rates and promising survival outcomes.